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The idiotypic (Id) 1 determinants of surface Ig of B cell iymphoma are excellent 
examples of tumor-specific markers (1-3).  Anti-Id raised against such tumor- 
derived Id react almost exclusively with the malignant B cell clone and not with 
normal cells in the host (4). Consequently, such antibodies have been useful both 
as therapeutic agents and as reagents for the study of the biology of these tumors 
(4-1 1). The mechanism of the antitumor effect of passively administered anti-Id 
has been assumed to involve the direct binding of the antibodies to the tumor 
cells in vivo, followed by cell destruction by host effector mechanisms such as 
complement, natural killer cells, and macrophages. However, some observations 
(12,  13) suggest the possibility of indirect mechanisms, such as the induction of 
immunoregulatory Id networks involving tumor-specific suppressor T  cells. 
Immunization with intact Id proteins,  isolated light (L) chains, or even the 
variable  (V)  domain  of the  L  chain  (VL) has  been  shown  (14-18)  to  induce 
immune responses that are  Id-specific, and that are capable of regulating the 
differentiation of tumor cells.  These immune responses also can confer a state 
of resistance to tumor growth. Recently (19-22), synthetic peptides comprising 
the amino acid sequences of the hypervariable regions of heavy (H) or L chains 
have  been  reported  to  be  capable  of inducing the  production  of antibodies 
reactive with  Id determinants of intact Ig molecules.  Herein, we explore the 
feasibility of using synthetic peptides comprising hypervariable region sequences 
of an H  chain to generate syngeneic antibodies specific for the Id determinants 
on the surface of a B cell tumor. 
We have determined the nucleic acid sequence of the V. gene expressed by a 
B lymphoma, synthesized peptides corresponding to the second and third hyper- 
variable regions, and produced both polyclonal and monoclonal antibodies (mAb) 
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against  these peptides.  We demonstrate that  polyclonal antisera  raised  against 
the peptides failed to react with the intact IgM.  However, a small percentage of 
mAb  made  against  one  complementarity-determining  region  (CDR)  peptide 
(CDR3) did react with an Id determinant expressed both by the isolated/~ chain 
and the intact IgM molecule. Three such mAb were characterized. They bound 
the  intact  IgM  with  markedly  lower  affinity  than  did  anti-Id  that  had  been 
produced  against  the  intact  protein.  Vaccination  of animals  with  the  CDR3 
peptide  did  not  reproduce  the  immunity  to  tumor  challenge  that  could  be 
obtained by vaccination with the intact IgM protein. 
Materials and Methods 
Mice.  C3H/HeN and C3H/HeN ×  BALB/c Fl mice were purchased from Simonsen 
Laboratories (Giiroy, CA),  or bred at the  Laboratory Animal  Facility at the  Stanford 
University Medical School. 
Tumor and Cell Lines.  38C13, a carcinogen-induced B cell tumor, was serially trans- 
planted in syngeneic C3H mice (23). This tumor and its in vitro adapted cell line express 
IgM (K) on the cell membrane but do not secrete Ig. A  high  Id-secreting cell line was 
established by fusion between the 38C13 tumor and the nonsecreting BALB/c myeloma 
cell line P3X63Ag8.653 (24). 
Sequence of the 38C13 # Chain.  The sequence of FR4, CDR3, FR3, and part of CDR2 
of the 38C13 t~ chain was obtained by direct messenger RNA (mRNA) sequencing (25, 
26) using a synthetic oligonucleotide primer. Poly A ÷ mRNA was isolated from the high 
Id-secretor cell line following a described protocol (27). Based on the known sequence of 
the  constant (C)  region of the #  chain of mouse IgM  (28),  the  following primer was 
synthesized: d(CAGGAGACGAGGGGGAA). This sequence was designed to hybridize to 
the C region of/~ chain mRNA near the V-C region junction; more precisely, 24 bases 
into the C region where the nucleotide sequence for murine and human mRNA (29) is 
identical. Hence, the same primer can be used to sequence V regions of mRNA of murine 
and human source. 
A second method was used to confirm the sequence determined from the RNA and to 
extend the sequence to include the entire V. region. A complementary DNA (cDNA) 
library of 38C13 B cell tumor poly A + mRNA, cloned into the expression vector ), gt 11, 
was kindly provided by Dr. Tom St. John (Stanford University). A clone containing a 2.2 
kilobase (kb) cDNA insert coding for the # chain was isolated by immunologic screening 
(30).  This  clone  was  hybridized  to  a  32p-labeled  cDNA  probe  obtained  by  reverse 
transcription of the mRNA using the synthetic oligonucleotide as primer. This confirmed 
the immunologic screening. A 550 base pair (bp) Eco RI-Sma I fragment containing the 
entire V region was isolated from this cDNA and subcloned in M13 mp 10 (31), usingJM 
101 as host. The DNA sequence was then determined (32). 
Peptide Synthesis and Conjugates.  Peptides were synthesized by solid-phase technique 
on a Beckman Model 990B peptide synthesizer using commercially available amino acid 
polystyrene resins and t-Boc protected amino acids (Peninsula Laboratories Inc., Belmont, 
CA) by methods that have been described previously (33, 34). All couplings were >99% 
complete, as determined by the reaction of the resin with ninhydrin (35).  The purity of 
the crude product was determined by high pressure liquid chromatography on a  C-18 
reverse-phase column (Merck and Co.,  Rahway,  NJ),  and by amino acid analysis.  The 
peptides used in these experiments were not purified further, since they all contained 
>90% of the desired product. The peptides were conjugated to bovine serum albumin 
(BSA) using succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate  (Pierce Chem- 
ical Co., Rockford, IL) as described (34). They were conjugated to thyroglobulin (Sigma 
Chemical Co., St.  Louis, MO) for immunization using a slightly different crosslinker, m- 
maleimidobenzoyl N-hydroxysuccinimide ester (Pierce Chemical Co.) (36). By using both 
a different carrier protein and crosslinker when using the peptide as an immunogen or as 
an antigen, we sought to minimize interference by antibodies generated against either the THIELEMANS ET  AL.  21 
carrier protein or the crosslinker. The degree of conjugation was quantitated by compar- 
ing the amino acid composition of the carrier protein before and after reaction with the 
peptide. The conjugates used in this study all contained between 15 and 25 peptides per 
molecule of BSA, and 25 to 35 peptides per 100 kilodaltons (kD) of thyroglobulin. 
Immunization and Fusion.  C3H/HeN mice were immunized intraperitoneally with 50 
ttg peptide-thyroglobulin conjugate in complete Freund's adjuvant, and boosted weekly 
in incomplete Freund's adjuvant for 4 wk. 3 d before fusion, an intravenous injection was 
given. Nucleated spleen cells were fused with P3X63Ag8.653 myeloma ceils, as described 
(37). 
Antibody  Assay.  An enzyme-linked immunosorbent assay (ELISA) was performed to 
determine the reactivity of polyclonal sera and mAb against the peptides and the 38C 13 
IgM protein.  Briefly, individual  wells were coated by incubation  with a  solution of 10 
ttg/ml of either the peptide-BSA conjugates, whole/z chains, or intact IgM proteins. For 
screening  of hybridoma  supernatants,  this  panel of different  targets was extended  to 
include  seven unrelated  mouse  IgM proteins.  Before use,  the coated microtiter plates 
were washed extensively with phosphate-buffered saline (PBS)  containing 0.05% Triton 
X  100 and were quenched with PBS containing 5% nonfat dry milk for at least 1 h at 
room temperatt~re. 
The 38C13  IgM protein was isolated from ascites fluid of a C3H/HeN X BALB/c F1 
mouse inoculated with the high Id-secreting cell line. This IgM protein was purified by 
ammonium sulfate precipitation  (45% saturation) followed by size fractionation over a 
column of Sephadex G-100.  Four  unrelated  IgM mAb, 4C5,  G10,  G4, and  G3,  were 
similarly isolated from ascitic fluid induced  by these  hybridomas, respectively. MOPC 
104E  and  TEPC  183  myeloma proteins  were  purchased  from  Bionetics  Laboratory 
Products (Charleston, SC), and used without further purification. Isolated H chains from 
38C13 IgM and 4C5 IgM were prepared as follows: IgM proteins were dialyzed against 
0.5 M Tris, 0.15 M NaCI, pH 8. Mercaptoethanol was added to a final concentration of 
0.4 M. The mixture was stirred in the dark at 37°C for 45 rain, then alkylated by adding 
a slight molar excess of 2-iodoacetamide. After 30 rain at room temperature, solid urea 
was added to a final concentration of 6 M. H and L chains were separated by chromatog- 
raphy using a column of ACA 44 Ultragel (LKB Instruments, Gaitbersburg, MD). 
Hybridoma supernatants or sera from mice immunized with the thyroglobulin conju- 
gates of the peptides or the 38C 13 IgM were serially diluted with PBS and 5% nonfat dry 
milk, and added to the wells of a microtiter plate precoated with target antigens. After 
incubation  for 8  h  at 4°C,  the plates were washed,  alkaline phosphatase-labeled goat 
antibodies specific for mouse "r chain (Southern Biotechnology Associates, Birmingham, 
AL) were added,  and the plates were incubated for 2 h  at room temperature.  Enzyme 
substrate  (p-nitrophenyl  phosphate,  disodium  salt)  was  added  to  each  well,  and  the 
absorption at 405 nm (A405) was measured by an ELISA reader. 
Sodium Dodecyl Sulfate-Polyacrylamide  Gel Electrophoresis (SDS-PAGE)  and Western Blot 
Transfer.  The various monoclonal IgM proteins were separated by SDS-PAGE on a 10% 
gel,  under  reducing  conditions.  The  proteins  were  electrophoretically  transferred  to 
nitrocellulose  (Millipore,  Bedford,  MA)  in  a  Trans-BIot  Cell  (Bio-Rad  Laboratories, 
Richmond, CA) and treated with PBS with 5% nonfat dry milk at 37°C for several hours 
to  saturate  the  matrix.  The paper was  incubated  with  antipeptide  hybridoma culture 
supernatant or control supernatant  for 2  h  at  4°C,  washed and treated with  5  x  105 
cpm/ml of lzSI-labeled sheep anti-mouse Ig (Amersham Corp., Arlington Heights, IL). 
The nitrocellulose filters were washed and exposed to x-ray film (XAR-2, Eastman Kodak, 
Rochester, NY). The electrophoretic transfer of the tt Ig chains was confirmed by treating 
the nitrocellulose with a  1:100 dilution of rabbit anti-mouse IgM (Bionetics Laboratory 
Products) in  PBS with 5% skim milk, followed by exposure to 5  x  105 cpm/ml of 1251- 
labeled protein A. 
Tumor Challenge.  The 38C 13 B lymphocyte cell line to be used in vivo was maintained 
in culture in RPMI 1640 medium containing 10% fetal calf serum, glutamine, antibiotics, 
and 5 ×  10  -5 M mercaptoethanol. Groups of 10 mice each were immunized with either 
peptide-thyroglobulin or  38C13  IgM-thyroglobulin conjugate.  The latter reagent  was 
prepared by the addition of 5 mg of solid thyroglobulin to 5 mg of 38C13 IgM in  1 ml 22  SYNGENEIC  ANTIIDIOTYPE  RESPONSES  TO  B  LYMPHOMA 
of 0.15  M  NaCI,  pH  4.5,  followed by an  8-h incubation at room temperature in  the 
presence of 5 mg 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (Pierce 
Chemical Co.). 
Animals were injected intraperitoneally five times, with 50 gg of thyrogiobulin conju- 
gate  per  injection,  essentially as  described  for  the  immunization of animals  before 
hybridoma production. The mice were then challenged with 102 38C 13 cells; a dose lethal 
to 100% of animals by day 30. The presence of tumor and the day of death were recorded. 
Results 
Nucleic Acid Sequencing of V,  from the 38C13 B Cell Tumor.  mRNA was isolated 
from the cytoplasmic RNA of the high Id-secreting cell line using an oligo-dT 
column. Direct sequencing of mRNA was performed using a  synthetic primer 
corresponding  to  the  amino  terminal  portion  of the  first  C  domain  of the  # 
chain. This provided the nucleic acid sequence coding for amino acid residues 
60  to  124  (Fig.  1).  The  remainder  of the  V,  sequence  was  derived  by  MI3 
sequencing of a  550 bp cDNA fragment containing the 5' untranslated, leader, 
and VH coding regions. The resultant nucleotide sequence determined by these 
two methods, as well as the corresponding amino acid sequence is shown in Fig. 
1. This U chain has a  V region of 126 residues, including a  diversity (D) region 
of 9 amino acids and a J2 (joining) region of 15 amino acids. 
Synthesis of Peptides Corresponding to the Hypervariable Regions.  Four peptides 
corresponding to  the  second and third hypervariable regions of the  38C13 
chain were synthesized. They were chosen based on consideration of secondary 
structure predictions.  The positions of the hypervariable regions are shown in 
Fig.  1,  whereas the predicted secondary structure  of this polypeptide chain is 
shown in Fig. 2. Two peptides were synthesized to span the second hypervariable 
1  l0 
GAG  GTG  AAG  CTG  GTG  GAG  TCT  GGA GGA GGC TTG  GTA  CAG CCT  GGG GGT  TCT  CTG  AGA CTC 
giu  val  lys  leu  val  glu  ser  gly  gly  gly  leo  val  gin  pro  gly  gly  ser  [eu  arg  leu 
30  40 
TCC  TGT  GCA GCT  TCT  GGT  TAC  ACC TTC  ACT  GAT  TAC  TAC  ATG  AGC TGG  GTC  CGC  CAG  CCT 
ser  cys  aJa  aJa  ser  gly  tyr  thr  phe  thr  asp  tyr  tyr  met  ser  trp  val  arg  gin  pro 
CDRI 
50 
CCA GGG  AAG  GCA CTT  GGA  TGG  TTG  GCT  TTG  ATT  AGA AAC AAA GCT  AAT  GGT  TAT  ACA ACA 
pro  gly  lys  ala  leu  gly  trp  |eu  ala  leu  lie  arg  asn  lys  ala  asn  giy  tyr  thr  thr 
CDR2 
60  70 
GAG TAC  AGT  GCA TCT  GTG  AAG  GGT  CGG TTC  ACG  GTC  TCC  AGA GAT  AAT  TCC  CAA  AGC ATC 
glu  tyr  ser  aJa  ser  vaJ  lys  g[y  arg  phe  thr  val  set  arg  asp  ash  ser  gin  ser  iJe 
80  90 
CTC  TAT  CTT  CAA ATG  AAT  GCC  CTG  AGA GCT  GAG  GAC AGT  GCC  ACT  TAT  TAC  TGT  GCA  AGA 
leu  tyr  leu  gin  met  asn  ala  leo  arg  ala  glu  asp  set  ala  thr  tyr  tyr  cys  ala  arg 
100 
GAT  CCC AAT  TAC  TAC  GAT  GGT  AGC TAC  GAA GGG TAC  TTT  GAC TAC  TGG  GCG  CAA GGC ACC 
asp  pro  ~sn  tyr  tyr  asp  gly  ser  tyr  glu  giy  tyr  phe  asp  tyr  trp  ala  gln  gly  thr 
CDR3 
II0 
ACT  CTC  ACA  GTC  TCC  TCA 
thr  leu  thr  val  ser  ser 
FIGURE  1.  Nucleotide  and translated amino acid sequence of the 38C13 # chain, CDR and 
amino acid number are according to Kabat (38). THIELEMANS  ET  AL.  23 
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FIGURE 2.  Location of the four oligopeptides within the sequence of the  38C13  /~ chain, 
their predicted secondary structure (39), and their relative hydrophilicity. The relative hydro- 
philicity of the protein was calculated by a  moving average over six residues using the values 
assigned by Kyte and  Doolittle (40).  Positive values correspond to the hydrophilic regions. 
Lines are written over polar amino acids; either positive or negative signs indicate charged 
amino acids. 
region,  CDR2Y  (NH2-CIRNKANGYTTEY-COOH)  and  CDR2C (NH2-GYT- 
TEYSASVHGRFTC-COOH) (using one-letter amino acid code). Each contains 
a predicted reverse turn distal to its attachment to the carrier protein. Similarly, 
CDR3S (NH2-YDGSYEGYDYC-COOH) and CDR3L (NH~-ARDPNYYDGSYE- 
GYFDYC-COOH)  correspond  to  the  residues  within  the  third  hypervariable 
region. The longer sequence includes a highly predicted reverse turn in its amino 
terminal region that is absent in the shorter analogue. 
Polyclonal Anti-CDR3 Sera Bind to Peptide and Isolated H Chains but Fail to Bind 
the Native IgM.  Mice were immunized by five intraperitoneal injections of either 
the  CDR3L-  or  CDR3S-thyroglobulin  conjugate.  Pooled  immune  sera  were 
analyzed for their ability to bind the immunizing peptide and to crossreact with 
either 38C 13/~ chain or intact 38C13 IgM. These sera were compared with the 
sera from animals immunized  with intact  38C13  IgM conjugated to thyroglob- 
ulin, and with an irrelevant peptide conjugate as a control. 
As  shown  in  Fig.  3,  CDR3L-thyroglobulin  elicited  a  strong  antipeptide  re- 
sponse in the animals (Fig. 3 A), as well as a response against the isolated H chains 24  SYNGENEIC  ANTIIDIOTYPE  RESPONSES  TO  B  LYMPHOMA 
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FIGURE 3.  Binding  ofanti-CDR3L (solid squares) and anti-38C-13 IgM (solid circles) pooled 
antisera to wells precoated with CDR3L-BSA  conjugate (A), 38C-13 # chain (B) and 38C-13 
IgM (C). 
of 38C13  IgM  (Fig.  3B).  However, this  serum  failed to bind  intact  IgM  (Fig. 
3 C). As expected, the sera from animals immunized with the intact 38C13 IgM 
showed a  strong  reaction  against  the  intact  protein  (Fig.  3C).  However,  this 
serum  reacted with the  isolated H  chain  to approximately  the same degree as 
the antipeptide sera (Fig. 3B). Interestingly, the antiserum raised against 38C 13 
IgM did react slightly with the peptide (Fig.  3A). Neither anti-CDR3L nor anti- 
38C13  immune  serum reacted with the  isolated H  chain of an irrelevant  IgM 
(4C5),  demonstrating  their  Id  specificity  (data  not  shown).  Sera  from  mice 
immunized with the control peptide-thyroglobulin conjugate showed no reactiv- 
ity with any of these antigens. 
Similarly, the mice immunized with the CDR3S-thyroglobulin conjugate gen- 
erated  a  significant  antipeptide  response.  This  immune  serum  also  reacted, 
although to a lesser extent than the anti-CDR3L immune serum, with the isolated 
chain. However, there was no reactivity with the 38C 13 IgM protein detectable 
above background (data not shown). 
mAb  Elicited  by  CDR3L  Bind  to  the  #  Chain,  and  to  the  Native  IgM.  The 
antipeptide immune response was dissected further by the production of hybrid- 
omas.  The  spleens  of mice  hyperimmunized  with  either  CDR3L-,  CDR3S-, 
CDR2Y-, or 'CDR2C-thyrogiobulin conjugates were removed, and the cell sus- 
pension was fused to P3X63Ag8.653 myeloma cells. Hybrids were selected for 
growth  in  HAT medium  (hypoxanthine,  aminopterin,  thymidine).  The  super- 
natants  of growing hybrids were tested for antipeptide and antiprotein  activity 
after at least two changes of the original growth medium. 
Hybridomas producing antibodies against the immunizing peptide were found 
in each fusion with an overall frequency of 9-15% of the obtained hybrids (30- 
80% of the seeded wells). However, antibodies crossreacting with intact  38C13 
IgM were obtained only when CDR3L-thyroglobulin was used as immunogen. 
In  this  case,  65%  of the  seeded  wells  were  positive  for  hybrid  growth.  53 
hybridoma supernatants (14% of growing hybrids) were reactive with the CDR3L 
peptide.  23  of these supernatants  reacted with  the isolated  H  chain  of 38C13 
IgM.  The supernatants  of 10 of these hybridomas also reacted with the intact 
38C13  IgM.  These  supernatants  were  unreactive  with  plates  coated  with  the 
irrelevant 4C5 ~ chain or IgM. 
The  frequencies  given  above  are  likely  to  be  overestimates,  because  the THIELEMANS  ET  AL.  25 
screening assays were performed on hybrids that had not been subcloned.  For 
instance, ~>25% of these supernatants could be shown to contain more than one 
IgG  subclass.  On  the  other  hand,  because  of the  necessity  to  use antibodies 
specific for mouse 3" chains as the detecting reagent, we have excluded antibodies 
of the IgM isotype from the analysis. 
10  of the  hybridomas  that  were  stable  in  producing  antibody  against  the 
CDR3L peptide were subcloned and subjected to further analysis (Table I). 7 of 
these 10 mAb reacted with the isolated 38C 13 H chain. Of these, only three also 
reacted with the intact 38C13 IgM. All of these antibodies showed Id specificity 
because  they did  not  react  with  any  of the  other  six  IgM  proteins.  Variable 
background is seen in this assay due to slight contamination  of the IgM prepa- 
rations with IgG. 
The crossreactivity of these hybridomas with the isolated # chains, and the Id 
specificity were further  examined  using immunoblots.  The same IgM proteins 
that  had  been used for the  ELISA assays were subjected to SDS-PAGE under 
reducing  conditions,  electrophoretically  transferred  to  nitrocellulose,  probed 
with each of the 10 antipeptide antibodies, and detectd with an 125I-labeled anti- 
mouse 3, chain reagent (Fig. 4). The same mAb that had reacted with the isolated 
# chain in ELISA assay also reacted in this assay. Once again, the reaction showed 
Id specificity for 38C13. Variable IgG contamination of the different irrelevant 
IgM preparations is once again evident, accounting for the spots in the 3' chain 
region of the gel. 
To ascertain that the crossreactivity of the mAb was indeed peptide induced, 
we performed the inhibition tests shown in Fig. 5. The reactivity of the antipep- 
tide antibodies with  38C13  IgM,  38C13  #  chains,  and  CDR3L-BSA conjugate 
could be inhibited  by preincubation  of the antibodies with  free CDR3L-BSA. 
Preincubation  of these antibodies with the irrelevant  peptides such as CDR2Y 
(Fig.  5) did not affect binding  to any of these targets.  These inhibition  curves 
TABLE  I 
Induction of  anti-ld Using CDR3L Peptide 
A40s (× 10  s) using various antibodies* 
CDR3L  38C13  38C13  4C5  4C5  MOPC  TEPC 183  G4  G3  GI0 
BSA  H chain  IgM,  H chain  IgM,  104E lgMx  IgM,  IgMx  lgM~  lgMx 
Anti-human Id  t  0  3  0  0  17  0  14  15  20  50 
16D  1,410  290  53  6  28  0  25  30  46  120 
17B  1,500  943  316  0  32  0  24  85  63  120 
17D  1,500  1,012  393  7  $2  0  28  81  54  120 
II! 10 D  1,500  650  20  3  29  0  23  91  59  130 
Ill 11 D  1,500  1,092  161  3  34  0  14  87  60  131 
IV 6 G  1,500  1,016  521  1  33  0  13  45  62  126 
IV 9 F  742  42  0  0  37  0  14  50  68  128 
V1 7 B  1,I00  163  0  0  39  0  11  40  95  130 
II 6 E  1,500  14  0  0  37  0  15  24  88  128 
I1 6 F  1,500  36  5  7  16  0  17  30  73  120 
Goatanti-mouse  --  343  853  175  1,500  730  1,500  1,500  640  534 
IgM  ! 
Antipeptide mAb were  assayed  as undiluted culture supernatants.  Bound antibodies were  detected with alkaline phosphatase-conjugated 
goat anti-mouse lgG and substrate.  The numbers represent A40s measured after 60 min incubation at room temperature. All supernatants 
were tested in triplicate. 
* Antigens were coated at 10 #.g/ml. 
* A monoclonal anti-human ld was used as negative control. 
i Alkaline phosphatase-conjugated goat anti-mouse lgM was used to detect the IgM and isolated  H chains. THIELEMANS  ET  AL. 
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FIGURE  .5.  InhibitionbyBSA-conjugatedpeptidesofantipeptideantibodybindingtoantigen- 
coated plates. Decreasing amounts of CDR3L-BSA  (solid circles) or CDR2Y-BSA conjugate 
(solid squares) were mixed with a fixed amount ofmAb (I, IV6G;//, 17D; and 111,  17B). After 
1 h incubation at room temperature, 50 ~tl of this reaction mixture was transferred to microtiter 
plates coated with CDR3L-BSA (A), isolated 38C-13 #  chain (B), or 38C-13  IgM (C). After 
overnight incubation at 4°C,  enzyme-labeled goat anti-mouse IgG was added to each well. 
Enzyme substrate was added, and A40~ measured 1 h later. 
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FIGURE 4.  Nitrocellulose blots of reducing SDS-PAGE probed with antipeptide mAb. The 
region of the gel containing the H  chains is shown. The upper two panels show the control 
blots indicating the position of the eight different # chains probed with rabbit anti-mouse IgM 
(upper left; positive control) and the reactivity of llSI-labeled sheep anti-mouse IgG after 
incubation with an irrelevant mouse mAb (upper right; negative control). Lanes 1-8 represent 
different murine ~t chains: 1, 38C-13; 2, 4C5; 3, RBC; 4, MOPCI04E,  5; TEPC183; 6, G10; 
7, G3; 8, G4. The antipeptide mAb used to probe the nitrocellulose blots is indicated under 
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demonstrated that minimal amounts of CDR3L peptide could inhibit the binding 
of the  antibodies  to  the  peptide-conjugate,  isolated  H  chains,  or  intact  IgM. 
However,  there  was a  significant difference in the  inhibitor concentration re- 
quired; ~ 10 times the amount of inhibitor peptide was necessary to inhibit 50% 
of antibody binding to the peptide conjugate as compared with the intact IgM. 
The  varying  inhibitor  requirement  could  be  due  either  to  variation  in  the 
concentration of the epitope on the plate in the three cases, or to a difference in 
affinity of the antibody for the different targets. The antipeptide antibodies were 
compared to anti-Id mAb raised against the intact Ig, 4C8,  and  3H5  (Fig.  6). 
The idiotope(s) recognized by these antiprotein antibodies require the association 
of both H  and L chains. Identical amounts of each of the antibodies were added 
to the wells of a  microtiter plate precoated with 38C13  IgM, assuring that the 
anti-Id and  the  idiotope  concentration  was  identical  for  the  antibodies  being 
compared.  Fig.  6  shows that  the antiprotein  antibodies  4C8  and  3H5,  raised 
against the intact protein, showed at least two orders of magnitude higher avidity 
(the concentration required to occupy half the antigenic sites) than the cross- 
reacting antipeptide antibodies. 
Immunization  with  IgM Induces  Tumor  Immunity  but Immunization  with CDR 
Peptide Does Not.  Normal C3H/HeN  mice injected weekly with  38C13  IgM- 
thyroglobulin conjugate produced demonstrable anti-Id within 3 wk. When these 
mice  were  challenged with a  lethal dose  of tumor  cells,  a  high fraction were 
resistant  to  tumor  growth  for  observation  periods  up  to  100  d  after  tumor 
inoculum. In a series of five experiments, the degree of tumor protection ranged 
from 60 to 100% of the immunized mice. As long as the 38C13 IgM protein was 
coupled  to  an  immunogenic  carrier,  adjuvant  was  unnecessary,  and  a  single 
injection of the conjugate was sufficient to produce  long-lasting immunity. A 
typical experiment is shown in Fig. 7  (Maloney, Kaminski, and Levy, in prepa- 
ration). 
In contrast, animals immunized with the CDR3L peptide conjugate developed 
tumors and died with a time course identical to the control animals (Fig. 7). The 
progressing  tumors  in  the  animals  were  all  Id  ÷,  since  all  these  animals  had 
developed increasing amounts of the 38C13  IgM protein  in  their sera  before 
death. 
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FIGURE 6.  Comparison of conventional anti-ld antibodies with antipeptide antibodies. Puri- 
fied anti-ld antibodies, 4C8 (open circles) and 3H5 (open squares), and antipeptide antibodies 
17B (closed circles), 17D (closed triangles), and IV6G (closed squares) were added to wells 
precoated with 38C-13 IgM. Starting at 10 ttg/ml, the antibody solution was diluted over 16 
wells. Bound antibody was detected by addition of goat anti-mouse IgG. The color develop- 
ment (A405) was measured 30 rain after the addition of the enzyme substrate. THIELEMANS  ET  AL.  29 
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FIGURE  7.  Tumor  immunity induced by  immunization with idiotype.  10  C3H/HeN  mice 
were immunized five times at weekly intervals with thyroglobulin conjugates of 38C-13  IgM 
(closed circles), control peptide (closed triangles), and CDR3L peptide (closed squares). 7 d 
after the last immunization,  mice were inoculated  with 102 38C13 tumor cells. 
Discussion 
Several  reports (19-22)  have appeared recently in which synthetic peptides 
were used to induce antisera that react with Id determinants of Ig. Peptides of 
13 to 16 amino acids in length, spanning CDR3 of the H chains (19, 20),  CDR2 
of the  L  chain (22),  and J. (21)  have all led to antibody responses that could 
recognize  not  only  the  appropriate  isolated  protein  chains,  but  the  specific 
assembled native Ig molecules. Typically, these antisera have been characterized 
by sensitive ELISA assays or immunoblotting procedures. 
We have extended the basic observation that peptides can induce an anti-Id 
immune response in a system in which the biologic relevance of these responses 
can be tested. We have used a B cell tumor in which syngeneic anti-Id immune 
responses can be induced against the intact Id protein produced by the tumor. 
These immune responses include anti-Id antibodies, as well as immunity to tumor 
challenge, which is presumably based on a T  cell mechanism. 
The amino acid sequence of the Ig H chain produced by the B cell tumor was 
deduced from nucleic acid sequencing. This was done by a combination of direct 
mRNA sequencing and the sequencing of a cloned V, cDNA fragment. Both of 
these  methods provided the sequence of the third hypervariable region.  The 
RNA sequencing method had the advantage of speed and direct applicability to 
human tumors, since it was based on a primer hemologous to a sequence in the 
first C #  exon, which is identical in mouse and man. However, this method is 
critically  dependent  on  the  quality  of the  RNA  preparation.  Also,  a  single 
sequencing reaction did not allow determination of the sequence beyond the 
second hypervariable region (150-200  nucleotides upstream from the primer). 
This method could be enhanced by the use of a second, upstream primer based 
on the sequence determined in the first reaction. Instead, we chose in this case 
to complete the sequence using a cloned cDNA fragment. 
The  homology of the  38C13  variable  region  with a  murine  V.  region  of 
subgroup III allowed for the identification of the three hypervariable regions. 
Linear  peptides  of CDR2  and  CDR3  were  chosen  based  on  the  predicted 
secondary structure of these areas. Only if the peptide adopts a similar confor- 
mation to what it maintains in the intact protein  will  the peptide successfully 
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ary  structures  in  proteins,  s-helices,  strands  of B-pleated  sheets,  and  reverse 
turns, we believe reverse turns have the greatest probability to exist in a short 
linear peptide, because of the energy requirements in their formation. Turns 
are thought to be formed in Ig and other globular proteins by the association of 
two  regions  of hydrophobic amino acids  located  on  either  side  of the  turn. 
Consequently, the majority of residues involved in  turn formation can be  in- 
cluded in a linear peptide. In contrast, sheet and helix formation and subsequent 
stabilization rely far more on through-space interactions. Such associations as the 
packing of a hydrophobic face of a helix or sheet on the hydrophobic core of a 
globular protein or the interstrand hydrogen bonds in a B-pleated sheet will not 
be  present  in  a  short  linear peptide.  We do  not assume that the  synthesized 
peptides will exist exclusively as reverse turns, but rather that they will have the 
lowest energy requirements to assume that conformation. 
We  synthesized  two  peptides  corresponding  to  CDR2  and  one  to  CDR3 
(CDR2Y and CDR2C), (CDR3L). Each of these peptides contains a reverse turn 
distal to its site of attachment to the carrier protein.  To test our ideas on the 
importance of turns in a peptide immunogen, we also synthesized CDR3S, which 
is identical to CDR3L except that it lacks the predicted reverse turn. All of the 
peptides elicited a  roughly equal antipeptide response.  Antibodies against the 
two CDR2  peptides failed to recognize the isolated H  chain.  Antisera against 
both CDR3S and CDR3L reacted with the isolated # chain, but those elicited by 
CDR3L  reacted  to  a  greater  degree.  However,  only  the  antibodies  against 
CDR3L  reacted  with  the  intact  assembled  IgM  protein,  thereby  providing 
support  for the importance of the predicted reverse  turn in this region.  The 
antibodies that crossreacted with the intact IgM were present in low concentra- 
tion in polyclonal serum. Such antibodies were detected only by isolating individ- 
ual hybridoma clones. Their relative reactivities against the peptide, the isolated 
H  chain, and the intact IgM were compared.  Not surprisingly, their ability to 
bind the intact Ig was much less than their ability to bind the peptide against 
which  they were  induced.  All  of the  interactions were  shown  to  be  specific, 
because they could be inhibited by the immunizing peptide. Comparison of the 
antipeptide mAb with those elicited by the intact Ig revealed that the two classes 
of antibodies dramatically differed in their ability to bind the intact IgM. The 
anti-Id generated against the intact  IgM bound the protein with at  least two 
orders of magnitude greater avidity than the antipeptide antibodies. 
We believe that both the low number of crossreactive antibodies and their low 
avidity relative  to antiprotein antibodies is  due  to  the  lack  of a  well-defined 
conformation in the peptide. Linear peptides are capable of stimulating a large 
number of B cell clones to produce antibody, only a small fraction of which will 
crossreact with the  intact protein.  The percentage of the antibodies that will 
crossreact will depend on the characteristics of the corresponding region in the 
protein. The highest percentage of crossreactive sera will result when antibodies 
are directed against a region lacking a well-defined conformation, i.e., a region 
that resembles a peptide, best exemplified by the amino or carboxyl termini of 
the protein. 
A peptide can adopt the identical conformation that it maintains in the intact 
protein either by a stochastic or an inductive mechanism. The stochastic model THIELEMANS  ET  AL.  31 
predicts,  (a) the percentage of antipeptide antibodies that crossreact with the 
intact protein depends on the statistical likelihood that the peptide exists in that 
particular conformation, and (b) a peptide is capable of occasionally stimulating 
the identical B cell clones that are elicited by the linear epitopes of the intact 
protein. If a peptide triggers a humoral response by this mechanism, some of the 
antipeptide mAb produced should crossreact with the intact protein with equal 
avidity as those elicited by the linear immunogenic regions of the protein. 
In contrast, if the conformation of the peptide is induced by the surface Ig, 
then (a) the fraction of the antipeptide antibodies that crossreact with the intact 
protein is dependent on the free energy necessary to induce the peptide to adopt 
that particular conformation, and (b) the energy necessary to induce the peptide 
will be reflected in the surface Ig having a lower affinity constant for the peptide 
relative to the same peptide with a defined conformation. If the energy necessary 
for  the  induction  becomes  too  great,  the  clone  will  not  be  stimulated,  and 
antibody recognizing the peptide in that conformation will be absent from the 
humoral response. This mechanism predicts that linear peptides lacking a single, 
well-defined conformation will always elicit lower-avidity crossreactive antibodies 
than those engendered by the intact protein. 
Although  we  have  not  screened enough antipeptide  clones  to  allow  us  to 
distinguish between the two mechanisms, the results of the experiments in this 
report indicate that high-affinity, crossreactive anti-Id clones, if not impossible 
to generate, will be very difficult to obtain by using peptides lacking a defined 
secondary structure as immunogens. Moreover, the low-affinity anti-Id antibodies 
such as those elicited by the peptides are unlikely to play an important role in 
immune  regulation.  CDR3L  was  incapable  of inducing  tumor  immunity  in 
syngeneic animals, although native 38C13  IgM was very effective in doing so. 
This biologic test is, admittedly, extremely stringent. Peptides with fixed config- 
urations similar to epitopes in the native hypervariable regions might be able to 
induce  higher  affinity anti-Id  antibodies  with  greater  potential  physiological 
significance. 
Summary 
The nucleic acid sequence of the heavy chain variable region (V.) expressed 
by 38C13,  a  B cell tumor of C3H origin, was determined by a combination of 
direct (messenger RNA) mRNA sequencing by primer extension and comple- 
mentary DNA  (cDNA) isolation  and sequencing in  M13.  The V. amino acid 
sequence was  deduced,  and  hypervariable  regions  were  identified.  From  an 
analysis of predicted secondary structure, regions of predicted antigenicity were 
chosen, and a  series of synthetic peptides corresponding to CDR2  and CDR3 
(complementarity-determining region)  were  produced.  These  peptides  were 
coupled  to  protein  carriers and  used  to  immunize syngeneic C3H  mice.  All 
peptides gave rise to a  vigorous antibody response.  However, only the CDR3 
peptides induced antibodies that crossreacted with the isolated H  chain protein. 
Only one CDR3 peptide induced antibody-producing clones, isolated as hybrid- 
omas,  that  reacted with the intact  IgM  protein.  However, the appearance of 
these clones was a low-frequency event. All antibodies reacting with the H chain 
or the intact IgM protein were idiotypically specific for 38C 13. These monoclonal 32  SYNGENEIC ANTI1DIOTYPE  RESPONSES TO  B LYMPHOMA 
antiidiotype  (anti-Id)  antibodies,  raised  against  CDR3  peptides,  gave  strong 
reactions  in  enzyme-linked immunosorbent  assays and  immunoblots,  but  they 
were of low affinity compared to syngeneic anti-Id raised against the intact IgM 
protein. Moreover, while the intact IgM was capable of inducing tumor immu- 
nity, the CDR peptides were not able to do so. 
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